Literature DB >> 19224164

Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma.

Qinglei Gao1, Fei Ye, Xi Xia, Hui Xing, Yunping Lu, Jianfeng Zhou, Ding Ma.   

Abstract

In order to investigate the role of the PTEN expression in carcinogenesis and development of endometrial carcinoma and clarify whether and how PTEN and PI3K/Akt pathway relate to endometrial carcinoma, the expression of PTEN and phospho-Akt was detected by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) methods and Western-blot from 24 cases of endometrial carcinoma, 10 cases of endometrial atypical hyperplasia, 10 cases of endometrial hyperplasia, and 10 cases of normal endometrium. SP immunohistochemical methods were used to measure levels of PTEN protein expression in following 5 study groups: 31 cases of endometrium in proliferative phase, 30 cases of endometrium in secretory phase, 71 cases of endometrial hyperplasia, 25 cases of atypical hyperplasia and 73 cases of endometrial carcinoma. Immunostaining score of PTEN was 3.39+/-0.15 in proliferative phase, 1.90+/-0.21 in secretory phase, 3.34+/-0.29 in endometrial hyperplasia, 0.62+/-0.11 in atypical hyperplasia, and 0.74+/-0.19 in endometrial carcinoma, respectively. PTEN mRNA relative value in normal endometrium, endometrial hyperplasia, endometrial atypical hyperplasia, and endometrial carcinoma was 2.45+/-0.51, 2.32+/-0.32, 0.46+/-0.11, and 0.35+/-0.13 respectively. The expression levels of PTEN mRNA and protein in patients with endometrial carcinoma and atypical hyperplasia were significantly lower than in those of proliferative phase and with endometrial hyperplasia. The level of PTEN expression in patients with endometrial carcinoma was significantly related to tissue type (P<0.005), differentiation (P<0.05) and clinical stage (P<0.05), but not to depth of myometrium invasion (P>0.05). Western blot analysis revealed that Phospho-Akt level in PTEN negative cases was significantly higher, and there was a negative correlation between PTEN and phospho-Akt (r=-0.8973, P<0.0001). It was suggested that loss of PTEN expression was an early event in endometrial tumorigenesis. The phosphorylation of Akt induced by the loss of PTEN took part in the tumorigenesis and development of endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224164     DOI: 10.1007/s11596-009-0112-6

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  18 in total

Review 1.  Molecular and pathologic aspects of endometrial carcinogenesis.

Authors:  Jonathan L Hecht; George L Mutter
Journal:  J Clin Oncol       Date:  2006-10-10       Impact factor: 44.544

2.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.

Authors:  G L Mutter; M C Lin; J T Fitzgerald; J B Kum; J P Baak; J A Lees; L P Weng; C Eng
Journal:  J Natl Cancer Inst       Date:  2000-06-07       Impact factor: 13.506

3.  PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.

Authors:  Fujiyuki Inaba; Hitoshi Kawamata; Tadahisa Teramoto; Ichio Fukasawa; Noriyuki Inaba; Takahiro Fujimori
Journal:  Oncol Rep       Date:  2005-01       Impact factor: 3.906

4.  Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis.

Authors:  Piotr G Rychahou; JungHee Kang; Pat Gulhati; Hung Q Doan; L Andy Chen; Shu-Yuan Xiao; Dai H Chung; B Mark Evers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

5.  Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium.

Authors:  Ozlem Guzeloglu-Kayisli; Umit A Kayisli; Rafat Al-Rejjal; Wenxin Zheng; Guven Luleci; Aydin Arici
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

Review 6.  Why is PTEN an important tumor suppressor?

Authors:  Li Li; Alonzo H Ross
Journal:  J Cell Biochem       Date:  2007-12-15       Impact factor: 4.429

Review 7.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

Review 8.  Hormonal heterogeneity of endometrial cancer.

Authors:  Carsten Gründker; Andreas R Günthert; Günter Emons
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 9.  Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints.

Authors:  D Llobet; J Pallares; A Yeramian; M Santacana; N Eritja; A Velasco; X Dolcet; X Matias-Guiu
Journal:  J Clin Pathol       Date:  2008-10-31       Impact factor: 3.411

10.  The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.

Authors:  Anna Dubrovska; Sungeun Kim; Richard J Salamone; John R Walker; Sauveur-Michel Maira; Carlos García-Echeverría; Peter G Schultz; Venkateshwar A Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-30       Impact factor: 11.205

View more
  7 in total

Review 1.  Implications of Immunotherapy in Hepatobiliary Tumors.

Authors:  Aline Gottlieb; Jan Best; Ali Canbay
Journal:  Visc Med       Date:  2019-02-08

2.  Long Noncoding RNA HOTAIR Promotes Endometrial Carcinoma Cell Proliferation by Binding to PTEN via the Activating Phosphatidylinositol 3-Kinase/Akt Signaling Pathway.

Authors:  Xiao-Hui Zhang; Pin Hu; Yang-Qin Xie; Yong-Jun Kang; Min Li
Journal:  Mol Cell Biol       Date:  2019-11-12       Impact factor: 4.272

3.  Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.

Authors:  Bojana Djordjevic; Bryan T Hennessy; Jie Li; Bedia A Barkoh; Rajyalakshmi Luthra; Gordon B Mills; Russell R Broaddus
Journal:  Mod Pathol       Date:  2012-02-03       Impact factor: 7.842

4.  Possible roles of mmu-miR-141 in the endometrium of mice in early pregnancy following embryo implantation.

Authors:  Xueqing Liu; Rufei Gao; Xuemei Chen; Hailing Zhang; Anshun Zheng; Dehui Yang; Yubin Ding; Yingxiong Wang; Junlin He
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

5.  PTEN Inhibits Cell Proliferation, Promotes Cell Apoptosis, and Induces Cell Cycle Arrest via Downregulating the PI3K/AKT/hTERT Pathway in Lung Adenocarcinoma A549 Cells.

Authors:  Xiao-Xiao Lu; Lan-Yu Cao; Xi Chen; Jian Xiao; Yong Zou; Qiong Chen
Journal:  Biomed Res Int       Date:  2016-10-16       Impact factor: 3.411

6.  MiR-374b Promotes Proliferation and Inhibits Apoptosis of Human GIST Cells by Inhibiting PTEN through Activation of the PI3K/Akt Pathway.

Authors:  Zi-Wen Long; Jiang-Hong Wu; Ya-Nong Wang; Ye Zhou
Journal:  Mol Cells       Date:  2018-06-14       Impact factor: 5.034

7.  Relationship between polycomb-group protein BMI-1 and phosphatases regulating AKT phosphorylation level in endometrial cancer.

Authors:  Agnieszka Zaczek; Paweł Jóźwiak; Piotr Ciesielski; Ewa Forma; Katarzyna Wójcik-Krowiranda; Łukasz Cwonda; Andrzej Bieńkiewicz; Magdalena Bryś; Anna Krześlak
Journal:  J Cell Mol Med       Date:  2019-12-21       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.